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Abbasi et al. (1) raise excellent points about the current
and future states of type 2 diabetes risk prediction. Two
issues in particular are worth consideration.
First, our clinical and polygenic prediction models do
not include time-varying assessments of known risk factors
such as BMI and fasting glucose (2). Abbasi et al. are cor-
rect that doing so would likely improve the models’ pre-
dictive accuracy. Instead, we patterned our models on what
is more common in clinical practice. In many ways, the
Framingham Heart Study cardiovascular disease risk score
deﬁnes the paradigm of using a “snapshot in time” ap-
proach to risk assessment. That is, what can the character-
istics of a patient sitting in front of the clinician tell him or
her about that patient’s risk of an outcome 10 years from
now? The dynamic risk factors Abbasi et al. propose will be
especially salient if clinicians increasingly incorporate risk
factor trajectories into their clinical decision making.
Second, their tiered approach to risk stratiﬁcation (i.e.,
obtaining more resource-intensive information only among
those individuals whose history suggests higher risk)
places an appropriate emphasis on the risks, beneﬁts,
and costs of screening. We agree with their call for an
evaluation of such screening strategies, although we would
argue that anthropometry and basic laboratory analyses are
already routinely measured in the many clinical settings.
An interesting question, then, is whether collection of
genome-wide data will be increasingly routine in the clinical
setting or even brought by the patients themselves after
consulting genotyping services outside of the standard
clinical setting. We think our analyses show that even if
each individual had his or her genotype for common ge-
netic variation stored in the electronic medical record, its
marginal value in diabetes risk prediction would be small.
Whether more sophisticated genetic information available
soon from high-throughput whole-genome sequencing
with detailed functional annotation will improve type
2 diabetes risk prediction, drug targeting, or patient care
overall remains an important question for the future.
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